News

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.
Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...
Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...
Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.
Fridays offers a subscription-based weight loss service. Its program includes virtual consultations with a health care provider, compounded GLP-1 medications, lifestyle and nutrition coaching, and ...
Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...
A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...